Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.

Alessandro Pastorino,Maria Di Bartolomeo,Evaristo Maiello,Vincenzo Iaffaioli,Libero Ciuffreda,Gianpiero Fasola,Francesco Di Costanzo,Giovanni Luca Frassineti, Paolo Marchetti,Carlotta Antoniotti,Francesco Leone,Alberto Zaniboni,Giuseppe Aprile,Chiara Zilocchi,Alberto Sobrero,Roberto Bordonaro

Clinical Colorectal Cancer（2018）

引用 22|浏览39

暂无评分

摘要

Aflibercept combined with FOLFIRI was well tolerated when administered as second-line treatment for patients with mCRC in a real-life setting. It did not affect HRQL and showed similar rates of treatment-emergent adverse events as those observed in the VELOUR trial. No new safety signals were identified.

查看译文

关键词

Antiangiogenesis,Antivascular endothelial growth factor agents,HRQL,Metastatic colorectal cancer,Targeted therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要